Akebia Therapeutics, Inc.
US ˙ NasdaqCM ˙ US00972D1054

SecurityAKBA / Akebia Therapeutics, Inc.
InstitutionMackenzie Financial Corp
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Mackenzie Financial Corp closes position in AKBA / Akebia Therapeutics, Inc.

On May 13, 2026 - Mackenzie Financial Corp filed a 13F-HR form disclosing ownership of 0 shares of Akebia Therapeutics, Inc. (US:AKBA) valued at $0 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 18, 2026 disclosing 272,503 shares of Akebia Therapeutics, Inc.. This represents a change in shares of -100.00% during the quarter. The current value of the position is $0 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 0 -272,503 -100.00 0 -100.00
2026-02-18 2025-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 272,503 7,223 2.72 432 -40.33 0.0005
2025-11-13 2025-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 265,280 16,678 6.71 724 -19.91 0.0009
2025-08-13 2025-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 248,602 11,044 4.65 905 98.25 0.0012
2025-05-07 2025-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 237,558 102,166 75.46 456 77.43 0.0006
2025-05-02 2024-12-31 13F/A-2 AKEBIA THERAPEUTICS COM 00972D105 135,392 122,252 930.38 257 1,411.76 0.0004
2025-02-20 2024-12-31 13F/A-1 AKEBIA THERAPEUTICS COM 00972D105 135,392 122,252 257 0.0003
2025-02-14 2024-12-31 13F Akebia Therapeutics Common Stock 00972D105 135,392 122,252 252 0.0004
2024-11-13 2024-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 13,140 -16,518 -55.69 17 -43.33 0.0000
2024-08-14 2024-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 29,658 4,919 19.88 30 -33.33 0.0000
2024-05-10 2024-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 24,739 1,580 6.82 45 60.71 0.0001
2024-01-30 2023-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 23,159 6,330 37.61 29 64.71 0.0000
2023-10-25 2023-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 16,829 -10,370 -38.13 18 -29.17 0.0000
2023-08-03 2023-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 27,199 -14,216 -34.33 25 4.35 0.0000
2023-04-24 2023-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 41,415 -26,718 -39.21 23 -41.03 0.0000
2023-02-14 2022-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 68,133 0 0.00 39 77.27 0.0001
2022-10-07 2022-09-30 13F Akebia Therapeutics Common Stock 00972D105 68,133 25,341 59.22 22 46.67 0.0000
2022-08-10 2022-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 42,792 20,929 95.73 15 -6.25 0.0000
2022-05-13 2022-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 21,863 583 2.74 16 -66.67 0.0000
2022-02-14 2021-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 21,280 21,280 48 0.0001
2021-02-10 2020-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 0 -20,800 -100.00 0 -100.00
2020-11-13 2020-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 20,800 -33,534 -61.72 52 -92.95 0.0001
2020-08-13 2020-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 54,334 -47,288 -46.53 738 -4.16 0.0020
2020-05-14 2020-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 101,622 65,202 179.03 770 234.78 0.0025
2020-02-13 2019-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 36,420 36,420 230 0.0006
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.